PureTech Health PLC PRTC Appoints Industry Veteran & Physician as CMO
August 13 2021 - 7:00AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
13 August 2021
13 August 2021
PureTech Health plc
PureTech Announces the Appointment Julie Krop, M.D., as Chief
Medical Officer
Industry veteran and board-certified physician to oversee
advancement of PureTech's clinical-stage Wholly Owned Pipeline
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases , today announced the
appointment of Julie Krop, M.D., as Chief Medical Officer. Dr. Krop
will oversee all clinical development, regulatory, CMC, and medical
affairs for the Company's advancing Wholly Owned Pipeline.
"We are pleased to welcome Julie to our senior leadership team
as our Wholly Owned Pipeline rapidly grows and advances across
multiple areas of significant patient need," said Daphne Zohar,
Founder and Chief Executive Officer of PureTech. "Julie is a
biopharmaceutical industry veteran with a wide breadth of expertise
across multiple therapeutic areas and orphan indications. Over the
course of her career, she has overseen development of eight
therapeutics that advanced through Phase 3, including three FDA
approvals. We believe her expertise in mid- to late-stage clinical
development, in addition to her extensive experience as a
board-certified physician and leader in regulatory affairs, will be
important assets as we advance our lead program, LYT-100, towards
potential registration-enabling development in idiopathic pulmonary
fibrosis and potentially other progressive fibrosing interstitial
lung diseases."
Dr. Krop joins PureTech from Freeline Therapeutics, a
clinical-stage gene therapy company, where she served as Chief
Medical Officer. Prior to this role, Dr. Krop served as Chief
Medical Officer of AMAG Pharmaceuticals (acquired by Covis group
for $647 million), where she oversaw clinical development,
regulatory affairs, clinical operations, medical affairs, program
management and pharmacovigilance. During her time at AMAG, Dr. Krop
was responsible for the oversight of three FDA approvals. Earlier
in her career, she held leadership positions at Vertex
Pharmaceuticals, Stryker Regenerative Medicine, Peptimmune,
Millennium Pharmaceuticals and Pfizer. Dr. Krop received her M.D.
from Brown University School of Medicine and completed an internal
medicine residency at Georgetown University Hospital. Additionally,
she completed fellowships in epidemiology, clinical trial design
and endocrinology as a Robert Wood Johnson Foundation Clinical
Scholar at the Johns Hopkins School of Medicine.
"I am thrilled to join the leadership team at PureTech during
such an exciting time in the Company's growth and clinical
development," said Dr. Krop. "PureTech's research and development
model is a truly unique approach that has fostered a broad wealth
of expertise within the Company that now powers the team's
innovative development efforts across multiple therapeutic
candidates. I look forward to helping drive PureTech's mission and
advancing an incredibly promising pipeline of investigational
therapies for patients in need."
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two that have received FDA clearance and
European marketing authorization, as of the date of PureTech's most
recently filed Annual Report on Form 20-F. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our therapeutic candidates, our expectations regarding the
appointment of our new Chief Medical Officer, and those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUQURUPGPGP
(END) Dow Jones Newswires
August 13, 2021 07:00 ET (11:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024